Cancer therapies have improved dramatically over the last several years, due to the development and discovery of novel therapies resulting from research conducted at AACI cancer centers. Among these are chimeric antigen receptor T-cell (CAR T) therapies and tumor infiltrating lymphocyte (TIL) therapy.

The AACI Cellular Therapy Initiative (CTI) facilitates collaboration between subject matter experts at AACI’s cancer centers through meetings, webinars, and various working group and task force projects. As the field continues to grow and novel treatments are approved by the U.S. Food and Drug Administration, the mission of CTI is to provide a forum where AACI cancer center CTI leaders can collect, evaluate, and share best practices that promote the efficient and effective operation of cellular therapy programs.